139 related articles for article (PubMed ID: 6601511)
1. The use of cellular immunoadsorbents to prepare polyclonal antibodies that distinguish between antigens derived from human melanoma cells and autologous lymphocytes.
Kelleher PJ; Mathews HL; Moore GE; Minden P
Cancer Immunol Immunother; 1983; 14(3):191-5. PubMed ID: 6601511
[TBL] [Abstract][Full Text] [Related]
2. The use of cellular immunoadsorbents to prepare antibody that distinguishes between syngeneic surface antigens on two guinea pig hepatocarcinomas.
Mathews HL; Brunda MJ; Minden P
J Immunol; 1980 Mar; 124(3):1141-7. PubMed ID: 7358979
[TBL] [Abstract][Full Text] [Related]
3. A glycoprotein of molecular weight 85,000 on human cells of B-lineage: detection with a family of monoclonal antibodies.
Letarte M; Iturbe S; Quackenbush EJ
Mol Immunol; 1985 Feb; 22(2):113-24. PubMed ID: 2579328
[TBL] [Abstract][Full Text] [Related]
4. Class 1 (unique) tumor antigens of human melanoma. Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody.
Real FX; Mattes MJ; Houghton AN; Oettgen HF; Lloyd KO; Old LJ
J Exp Med; 1984 Oct; 160(4):1219-33. PubMed ID: 6237165
[TBL] [Abstract][Full Text] [Related]
5. Tumor-specific T-cell clones recognize different protein determinants of autologous human malignant melanoma cells.
Notter M; Schirrmacher V
Int J Cancer; 1990 May; 45(5):834-41. PubMed ID: 2159436
[TBL] [Abstract][Full Text] [Related]
6. Production and characterization of xenogeneic antisera to tumor-associated antigen(s).
Gupta RK; Silver HK; Morton DL
J Surg Oncol; 1980; 13(1):75-89. PubMed ID: 6153230
[TBL] [Abstract][Full Text] [Related]
7. Purification and partial characterization of a shed 66 kDa melanoma-associated antigen identified by autologous antibody.
Vlock DR; Aul DJ; Toporowicz A; McCoy JP; Brown WE
Biochim Biophys Acta; 1991 Oct; 1080(1):1-10. PubMed ID: 1932077
[TBL] [Abstract][Full Text] [Related]
8. Identification and isolation of melanoma-associated antigens with monoclonal antibodies.
Ross AH; Mitchell KF; Steplewski Z; Koprowski H
Hybridoma; 1982; 1(4):413-21. PubMed ID: 6765324
[TBL] [Abstract][Full Text] [Related]
9. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells.
Topalian SL; Rivoltini L; Mancini M; Ng J; Hartzman RJ; Rosenberg SA
Int J Cancer; 1994 Jul; 58(1):69-79. PubMed ID: 7516926
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies to 125 kd and 95 kd proteins on human melanoma cells: comparison with other monoclonal-defined melanoma antigens.
Saxton RE; Mann BD; Morton DL; Burk MW
Hybridoma; 1982; 1(4):433-45. PubMed ID: 6208138
[TBL] [Abstract][Full Text] [Related]
11. Identification of several cell surface proteins of non-T, non-B acute lymphoblastic leukemia by using monoclonal antibodies.
Quackenbush EJ; Letarte M
J Immunol; 1985 Feb; 134(2):1276-85. PubMed ID: 3155538
[TBL] [Abstract][Full Text] [Related]
12. Isolation of naturally processed peptides recognized by cytolytic T lymphocytes (CTL) on human melanoma cells in association with HLA-A2.1.
Wölfel T; Schneider J; Meyer Zum Büschenfelde KH; Rammensee HG; Rötzschke O; Falk K
Int J Cancer; 1994 May; 57(3):413-8. PubMed ID: 8169004
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of the binding characteristics of monoclonal antimelanoma antibodies.
Herlyn M; Steplewski Z; Atkinson BF; Ernst CS; Koprowski H
Hybridoma; 1982; 1(4):403-11. PubMed ID: 6765323
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a novel neuroglandular antigen (NGA) expressed on abnormal human melanocytes.
Sikora LK; Pinto A; Demetrick DJ; Dixon WT; Urbanski SJ; Temple W; Jerry LM
Int J Cancer; 1987 Feb; 39(2):138-45. PubMed ID: 3804488
[TBL] [Abstract][Full Text] [Related]
15. A solid-phase radioimmunoassay to detect antibodies produced by hybridomas to antigens derived from human melanoma cells.
Kelleher PJ; Mathews HL; Woods LK; Farr RS; Minden P
Cancer Immunol Immunother; 1983; 14(3):185-90. PubMed ID: 6551193
[TBL] [Abstract][Full Text] [Related]
16. Isolation and partial characterization of melanoma-associated antigens identified by autologous antibody.
Vlock DR; Scalise D; Meglin N; Kirkwood JM; Ballou B
J Clin Invest; 1988 Jun; 81(6):1746-51. PubMed ID: 3384949
[TBL] [Abstract][Full Text] [Related]
17. Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies.
Chen YT; Stockert E; Chen Y; Garin-Chesa P; Rettig WJ; van der Bruggen P; Boon T; Old LJ
Proc Natl Acad Sci U S A; 1994 Feb; 91(3):1004-8. PubMed ID: 8302824
[TBL] [Abstract][Full Text] [Related]
18. Demonstration of a well-characterized tumor-associated antigen on melanoma cell surface.
Wong JH; Gupta RK; Morton DL
J Surg Oncol; 1988 Jul; 38(3):147-50. PubMed ID: 3292843
[TBL] [Abstract][Full Text] [Related]
19. The serologic response of patients with stage II melanoma to allogeneic melanoma cell vaccines.
Livingston PO; Kaelin K; Pinsky CM; Oettgen HF; Old LJ
Cancer; 1985 Nov; 56(9):2194-200. PubMed ID: 4052966
[TBL] [Abstract][Full Text] [Related]
20. Membrane-associated antigens on tumor cells from transitional-cell carcinoma of the human urinary bladder. I. Immunological characterization by xenogeneic antisera.
Schneider MU; Troye M; Paulie S; Perlmann P
Int J Cancer; 1980 Aug; 26(2):185-92. PubMed ID: 7203712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
